Accolade Inc
NASDAQ:ACCD

Watchlist Manager
Accolade Inc Logo
Accolade Inc
NASDAQ:ACCD
Watchlist
Price: 7.02 USD Market Closed
Market Cap: $575.6m

P/B

1.8
Current
No historical data
Comparison unavailable

Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.

P/B
1.8
=
Market Cap
$569.9m
/
Total Equity
$313m

Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.

P/B
1.8
=
Market Cap
$569.9m
/
Total Equity
$313m

Valuation Scenarios

Accolade Inc is trading above its 3-year average

If P/B returns to its 3-Year Average (1.8), the stock would be worth $7.02 (0% downside from current price).

Statistics
Positive Scenarios
2/4
Maximum Downside
0%
Maximum Upside
+71%
Average Upside
27%
Scenario P/B Value Implied Price Upside/Downside
Current Multiple 1.8 $7.02
0%
3-Year Average 1.8 $7.02
0%
5-Year Average 1.8 $7.02
0%
Industry Average 3.1 $12.04
+71%
Country Average 2.5 $9.69
+38%

Forward P/B
Today’s price vs future total equity

Not enough data available to calculate forward P/B

Peer Comparison

All Multiples
P/B
P/E
All Countries
Close
Market Cap P/B P/E
US
Accolade Inc
NASDAQ:ACCD
569.9m USD 1.8 -3.2
US
CVS Health Corp
NYSE:CVS
100.2B USD 1.3 56.7
US
Cigna Group
XMUN:CGN
68.5B EUR 1.9 13.2
US
Cigna Corp
NYSE:CI
73.7B USD 1.8 12.4
DE
Fresenius SE & Co KGaA
XETRA:FRE
22.9B EUR 1.2 18.1
DE
Fresenius Medical Care AG
XMUN:FME
23.1B EUR 1.7 23.6
US
Quest Diagnostics Inc
NYSE:DGX
21.9B USD 3.1 22.2
US
Laboratory Corporation of America Holdings
NYSE:LH
21.8B USD 2.5 24.8
DE
Fresenius Medical Care AG & Co KGaA
XETRA:FME
10.9B EUR 0.8 11.1
US
Guardant Health Inc
NASDAQ:GH
11.5B USD -115.6 -27.6
US
DaVita Inc
NYSE:DVA
10.6B USD -16.3 14.2
P/E Multiple
Earnings Growth PEG
US
Accolade Inc
NASDAQ:ACCD
Average P/E: 21.8
Negative Multiple: -3.2
N/A N/A
US
CVS Health Corp
NYSE:CVS
56.7
90%
0.6
US
C
Cigna Group
XMUN:CGN
13.2
19%
0.7
US
Cigna Corp
NYSE:CI
12.4
19%
0.7
DE
Fresenius SE & Co KGaA
XETRA:FRE
18.1
25%
0.7
DE
Fresenius Medical Care AG
XMUN:FME
23.6
15%
1.6
US
Quest Diagnostics Inc
NYSE:DGX
22.2
12%
1.9
US
Laboratory Corporation of America Holdings
NYSE:LH
24.8
27%
0.9
DE
F
Fresenius Medical Care AG & Co KGaA
XETRA:FME
11.1
15%
0.7
US
Guardant Health Inc
NASDAQ:GH
Negative Multiple: -27.6 N/A N/A
US
DaVita Inc
NYSE:DVA
14.2
19%
0.7

Market Distribution

In line with most companies in the United States of America
Percentile
39th
Based on 10 946 companies
39th percentile
1.8
Low
0 — 1.5
Typical Range
1.5 — 4.8
High
4.8 —
Distribution Statistics
the United States of America
Min 0
30th Percentile 1.5
Median 2.5
70th Percentile 4.8
Max 147 580.5

Accolade Inc
Glance View

Accolade, Inc. engages in the provision of personalized health and benefits solutions. The company is headquartered in Seattle, Washington and currently employs 2,350 full-time employees. The company went IPO on 2020-07-02. The Company’s customers are primarily employers that deploy Accolade in order to provide employees and their families members a single place to turn for their health, healthcare, and benefits needs. Its platform combines open, cloud-based intelligent technology with multimodal support from a team of empathetic and knowledgeable Accolade Health Assistants and clinicians, including nurses, physician medical directors, and behavioral health specialists. The firm leverages its integrated capabilities, connectivity with providers and the healthcare ecosystem, and longitudinal data to engage across the member population. Its offerings are: Accolade Total Benefits, Accolade Total Care, Accolade Total Health and Benefits, Accolade Boost, the Trusted Supplier Program, and Mental Health Integrated Care solutions.

ACCD Intrinsic Value
8.24 USD
Undervaluation 15%
Intrinsic Value
Price $7.02
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett